Document:

<PAGE>

                                                                   EXHIBIT 10.88

                        ADDENDUM TO EMPLOYMENT AGREEMENT

This addendum, dated February 14, 2003, reflects a modification to the
Employment Agreement (the "Agreement") between Viragen, Inc. ("Employer") and
Melvin Rothberg ("Employee").

Whereas, both Employer and Employee intend to modify Employee's Employment
Agreement dated July 1, 2001. It is agreed the following paragraphs shall be
added to the paragraph 5 of the Agreement.

         Effective February 14, 2003, Employer and Employee agree to reduce
         Employee's cash salary by 20%, from the adjusted amount of $181,500 per
         annum to $145,200 per annum resulting in a cash salary reduction of
         $36,300 per annum (the "Reduction").

         In lieu of cash consideration equal to the Reduction, Employer agrees
         to issue and Employee agrees to accept an amount of Viragen, Inc.
         common stock equivalent in value to the amount of the Reduction, valued
         at the closing market price at the end of each pay period.

         Employee acknowledges that common shares issued pursuant to this
         Addendum shall be unregistered shares under Securities and Exchange
         Commission guidelines. Employer agrees to use its best efforts to
         register these shares within 90 days of issuance.

         Both Employer and Employee agree and acknowledge that the Reduction is
         voluntary on the part of the Employee and may be unilaterally rescinded
         at any time.

         All other provisions of the Agreement shall remain unchanged.

                                                     VIRAGEN, INC.

/s/ Melvin Rothberg                                  /s/ Dennis W. Healey
-------------------------------                      ---------------------------
Melvin Rothberg                                      Dennis W. Healey
Employee                                             Exec. Vice President/CFO<PAGE>

                                                                   EXHIBIT 10.89

                                  VIRAGEN, INC.

                       OFFICERS AND DIRECTORS ALTERNATIVE
                             STOCK COMPENSATION PLAN

                                     ADOPTED
                                JANUARY 31, 2003

         WHEREAS, Viragen, Inc. (the "Company"), as a means to conserve cash,
may, from time to time, desire to issue its common shares to officers and
directors of the Company in lieu, in part or in whole, of salaries to officers
and payments to directors for services on the Board of Directors and committees
thereof; and

         WHEREAS, the issuance of common shares in lieu of such compensation
payments may be made from time to time upon mutual concurrence by the Company
and the officers and directors electing to receive such alternative
compensation;

         NOW, THEREFORE, the Company hereby establishes the Officers and
Directors Alternative Stock Compensation Plan (the "Plan") on the terms and
conditions hereinafter provided.

         1.       Stock may be issued in lieu, in part or in whole, of cash
compensation upon the mutual concurrence of the Company and the participating
officer and director.

         2.       The maximum amount of common shares included under the Plan
shall be 500,000 shares of common stock.

         3.       The term of the Plan shall be for five years from the date
hereof, and no common shares under this Plan may be issued following conclusion
of the term hereof, except for services completed prior to the term.

         4.       The stock to be issued under the Plan shall be valued based on
the closing price of the common shares of the Company on the American Stock
Exchange on the date of the meeting of the Board of Directors, or committee
thereof, provided the director has attended in person such meeting or has
participated through telephonic conference call facilities, subject to
appropriate adjustment as determined by the Board of Directors. In the case of
officers, the common shares shall be valued based on the closing price of the
common shares of the Company on the American Stock Exchange on the last date of
the relevant payroll period for the officer.

         5.       The Company will file an appropriate registration statement
under the Securities Act of 1933 in order to register the common shares to be
issued to officers and directors under the Plan, subject to any deferral
determined to be necessary to accommodate any financing of the Company.

<PAGE>

         6.       The Company reserves the right to terminate the Plan at any
time prior to the conclusion of its term, in which case no shares will be issued
under the Plan which have not theretofore been issued or committed to the
officers and directors.

         IN WITNESS WHEREOF, this Plan was adopted pursuant to the authorization
of the Board of Directors of the Company on the 31st day of January, 2003.

                                              BY ORDER OF THE BOARD OF DIRECTORS
                                              VIRAGEN, INC.

                                              By: /s/ Carl Singer
                                                  ------------------------------
                                                  Chairman of the Board

                                       2<PAGE>

                                                                   EXHIBIT 10.90

                             STOCK WARRANT AGREEMENT

WARRANT AGREEMENT, dated as of June 16, 2003 (the "Effective Date") between
Viragen, Inc. a Delaware Corporation (the "Company") and Douglas D. Lind, M.D.
("Consultant").

The Company hereby grants to Consultant a Warrant to acquire 250,000 shares of
Common Stock, par value $.01 per share, of the Company (the "Common Stock"),
subject to the following terms and conditions:

         1.       Grant of Warrant. The Company hereby grants to Consultant (the
"Warrant") to purchase up to 250,000, shares of Common Stock (the "Shares"), to
be transferred upon the exercise thereof, fully paid and nonassessable.

         2.       Exercise Price. The exercise price of the Shares subject to
the Warrant shall be at market at the date of grant, $0.26 per share. The
Company shall pay all original issue or transfer taxes upon the exercise of the
Warrant by Consultant.

         3.       Exercisability of Warrant; Rights and Privileges. Subject to
the provisions of Paragraph 6 hereof, the Warrant shall be exercisable by
Consultant commencing on the Effective Date, concurrent with the effective date
of Consultant's Consulting Agreement ("Exercise Date") for a period of five (5)
years.

All granted but unexercised Warrants shall continue to be fully exercisable in
accordance with the provisions herein:

                           (i)      if there occurs any corporate transaction
(which shall include a series of corporate transactions occurring within 60 days
or occurring pursuant to a plan), that has the result that shareholders of the
Company immediately before such transaction cease to own at least 66 2/3 percent
of the voting stock of the Company in a (a) reorganization, (b) consolidation,
(c) merger, (d) liquidation or (e) a similar of corporate transaction;

                           (ii)     if the shareholders of the Company shall
approve a plan of merger, consolidation, reorganization, liquidation or
dissolution in which the Company does not survive (unless the approved merger,
consolidation, reorganization, liquidation or dissolution is subsequently
abandoned); or

                           (iii)    if the shareholders of the Company shall
approve a plan for the sale, lease, exchange or other disposition of all or
substantially all the property and assets of the Company (unless such plan is
subsequently abandoned).

<PAGE>

         4.       Non-Assignability of Warrant. The Warrant shall not be given,
granted, sold, exchanged, transferred, pledged, encumbered, assigned or
otherwise disposed of by Consultant, other than by will, the laws of descent and
distribution or estate planning purposes, and during the lifetime of Consultant,
shall not be exercisable by any other person, but only by Consultant.

         5.       Method of Exercise of Warrant. Consultant shall notify the
Company by written notice, in the form of the Notice of Exercise attached hereto
(Attachment A), delivered to the Company's principal office, attention: Chief
Financial Officer.

                  Payment for the Shares shall be made by Consultant's check
payable to the order to the Company in full payment for the total exercise price
of the number of Shares purchased.

                  As soon as practicable after the receipt of such Notice of
Exercise and accompanying payment for the purchase of Shares, the Company shall,
at its principal office, tender to Consultant a certificate or certificates
issued in Consultant's name evidencing the Shares purchased by Consultant
hereunder.

         6.       Termination of Warrant. To the extent exercisable but not
exercised, the Warrant shall terminate upon the first to occur of the following
dates:

                  (a)      five (5) years from the Exercise Date as defined
herein if Consultant is still consulting with the Company pursuant to the June
15, 2003 Consulting Agreement, or

                  (b)      if the Consulting Agreement is terminated by the
Company:

                          i.       prior to the first anniversary of the
                           Consulting Agreement, six (6) months from
                           termination; or

                          ii.      subsequent to the first anniversary of the
                           Consulting Agreement, to the second anniversary, nine
                           (9) months from termination; or

                          iii.     subsequent to the second anniversary of the
                           Consulting Agreement, one (1) year from termination;

                  (c)      if the Consulting Agreement is terminated by
Consultant:

                          i.       prior to the first anniversary of the
                           Consulting Agreement, ninety (90) days from
                           termination;

                          ii.      subsequent to the first anniversary to the
                           second anniversary, six (6) months from termination;

                          iii.     subsequent to the second anniversary to the
                           third anniversary, nine (9) months from termination;
                           or

                                       2

<PAGE>

                          iv.      subsequent to the third anniversary, one (1)
                           year from termination.

                  Subject to the provisions of this paragraph, in the event of
Consultant's death, the exercisable but unexercised portion of the Warrant may
be exercised by the estate of the Consultant or by the person who acquired the
right to exercise the Warrant by bequest or inheritance or by reason of the
death of Consultant.

         7.       Securities Laws. The Company represents and warrants that (i)
all shares underlying the Warrants will be issued from shares authorized for
transfer under the applicable regulations of the Securities and Exchange
Commission on Form S-8; and (ii) such registration covering the shares
underlying the Warrants will be maintained as effective for the longer of (a)
term of the Consulting Agreement and any extensions thereof, if applicable, or
(b) the Exercise Period of the Warrants as defined herein.

         8.       Adjustment of Shares. If at any time prior to the expiration
or exercise in full of the Warrant, there shall be any increase or decrease in
the number of issued and outstanding shares of the Common Stock through the
declaration of a stock dividend or through any recapitalization resulting in a
stock split-up, combination or exchange of the Common Stock, then and in such
event:

                  (i)      appropriate adjustment shall be made in the maximum
number of Shares available for grant, so that the same percentage of the
Company's issued and outstanding Shares shall continue to be subject to Warrant;
and

                  (ii)     appropriate adjustment shall be made in the number of
Shares, and the exercise price per Share thereof, that remain unexercised under
the Warrant, so that the same percentage of the Company's issued and outstanding
shares of Common Stock shall remain subject to purchase at the same aggregate
exercise price.

Except as otherwise expressly provided herein, the issuance by the Company of
shares of its capital stock of any class, or securities convertible into shares
of capital stock of any class, either in connection with a direct sale of upon
the exercise of rights or warrants to subscribe therefore, or upon conversions
of shares or obligations the Company convertible into such shares or other
securities, shall not affect, and no adjustment by reason thereof shall be made
with respect to, the number of exercise price of the Shares that remain
unexercised under the Warrant.

Without limiting the generality of the foregoing, the existence of unexercised
Shares under the Warrant shall not affect in any manner the right or power of
the Company to make, authorize or consummate (i) any or all adjustments,
recapitalizations, reorganizations or other changes in the Company's capital
structure or its business; (ii) any merger or consolidation of the Company;
(iii) any issue by the Company of debt securities, or preferred or preference
stock that would rank above the Shares issuable upon exercise of the Warrant;
(iv) the dissolution or liquidation of the Company; (v) any

                                       3

<PAGE>

sale, transfer or assignment of all or any part of the assets or business of the
Company; or (vi) any other corporate act or proceeding, whether of a similar
character or otherwise.

         9.       No Rights as Stockholder. Consultant shall have no rights as a
stockholder of the Company in respect of the Shares as to which the Warrant
shall not have been exercised and payments made therefore as herein provided.

         10.      Binding Effect. Except as otherwise provided herein, this
Agreement shall be binding upon and inure to the benefit of the parties hereto,
their heirs, legal representatives, successors and permitted assigns.

         11.      Governing Law. This Agreement shall be governed by and
construed in accordance with the laws of the State of Florida, without giving
effect to the conflict of laws principles thereof. All terms not defined in this
Agreement shall have the same meaning as in the Plan.

         IN WITNESS WHEREOF, the parties have executed this Agreement as of the
day and year first above written.

                                                      VIRAGEN, INC.

                                                  By: /s/ Robert C. Salisbury
                                                      --------------------------
                                                      Robert C. Salisbury
                                                      Chief Executive Officer

                                                      CONSULTANT

                                                      /s/ Douglas D. Lind
                                                      --------------------------
                                                      Douglas D. Lind, M.D.

                                       4

<PAGE>

                                  ATTACHMENT A

                               NOTICE OF EXERCISE

The undersigned hereby irrevocably elects to exercise the within Warrant to the
extent of purchasing __________ shares of Common Stock of Viragen, Inc., a
Delaware Corporation, and hereby makes payments of $________ in payment
therefor.

                                            ________________________________
                                            Signature

                                            ________________________________
                                            Date

         INSTRUCTIONS FOR ISSUANCE OF STOCK AND CORPORATE RECORDS

Name:             ________________________________________
                  (Please type or print in block letters)

Address:          ________________________________________

                  ________________________________________

Social Security #: _______________________________________

Phone #: (____)___________________________________________

Fax #:   (____)___________________________________________

                                       5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00054-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00054-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00054-of-00352.parquet"}]]